Top Qs
Timeline
Chat
Perspective
Retatrutide
Chemical compound From Wikipedia, the free encyclopedia
Remove ads
Retatrutide (LY-3437943) is an experimental drug for obesity developed by American pharmaceutical company Eli Lilly and Company. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors).[1] It has been shown to achieve a more than 17.5% mean weight reduction in adults without diabetes but with obesity or preobesity (overweight) during a phase 2 trial.[2][3][4] In the trial, the participants who received the highest dose (12 mg) showed a mean weight reduction of 24.2% after 48 weeks.[4]
Remove ads
Chemistry
Retatrutide is a peptide with the following amino acid sequence[5]
YA¹QGTFTSDYSIL²LDKK⁴AQA¹AFIEYLLEGGPSSGAPPPS³
where letters with superscripted numbers refer to the following chemical modifications:
- "A¹" refers to 2-aminoisobutyric acid (Aib).
- "L²" refers to leucine modified with an α-methyl substituent (MeL, 2-methylleucine).
- "S³" refers to L-serinamide (L-serine with the carboxylic acid group replaced with a carboxamide).
- "K⁴" refers to L-lysine with the amino group at position 6 modified with a side chain; specifically, (AEEA)-(γ-Glu)-(C20 diacid) (where AEEA is 2-[2-(2-aminoethoxy)ethoxy]acetic acid, commonly used as a spacer group in synthetic peptides).
Remove ads
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads